We are talking about synthetic blood, for example for treating the wounded without the need to refrigerate and transport ...

Building an AI infrastructure for biotech. Bacteria that munch on cancer. How to best make a cold brew. All that and more in ...

Eli Casdin, Casdin Capital CEO, joins 'Closing Bell' to discuss the biotech sector, the stocks Casdin favors and much more.

Goldman Sachs' Salveen Richter joins 'Closing Bell Overtime' to talk how AI is benefiting the biotech sector.

February 2026 saw a major biopharma acquisition, four key buyouts, and licensing deals in antibodies, small molecules, and ...

The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.

UCB has entered the red-hot T-cell engager (TCE) space by paying $80 million for the rights to a Chinese biotech’s ...

With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter, ...

X4 Pharmaceuticals is a BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending ...

A Review of the «World Bank Group Country Climate and Development Report» (February 2026) Mauritius is no stranger to ...

Liquidia Technologies reports full-year 2025 results on Thursday before the market opens, a pivotal moment for the ...

MONTREAL, TORONTO and VANCOUVER, BC, March 4, 2026 /CNW/ – adMare BioInnovations is proud to announce the launch of ...